MoonLake’s Sonelokimab Achieves High Response Rates in HS After 12 Months
Sonelokimab shows strong 1-year results in HS, with many patients seeing clear skin, less pain, and better quality of life, with good safety.
/ 495 items
#XY Event-Driven Stocks↓
Pfizer Announces Departure of CFO Dave Denton, Names Interim Successor
Cecile Guegan named Interim CFO as the company reaffirms its 2026 guidance.
Novocure Stock Plunges After Phase 3 TRIDENT Study Fails to Meet Primary Goal
Novocure’s Phase 3 TRIDENT trial failed to show survival benefit from earlier TTFields initiation in newly diagnosed glioblastoma.
Biogen Acquires RayThera for Up to $1 Billion to Expand Immunology Pipeline
The deal adds multiple early-stage small-molecule immunology assets to Biogen’s pipeline, with the lead candidate entering Phase 1 in Q3 2026.
FDA Clears Path for AXPAXLI: Ocular Therapeutix Targets Late 2026 NDA Submission
Ocular Therapeutix has reached alignment with the FDA to submit the AXPAXLI NDA for wet AMD in Q4 2026, based on SOL-1 data and interim SOL-R safety results. Topline SOL-R data now expected in Q1 2028.
Jazz Pharmaceuticals Strikes Major Collaboration with AbCellera for Next-Generation Multispecific Antibodies
Jazz Pharmaceuticals and AbCellera enter a collaboration worth up to $876 million to develop next-generation T-cell engaging multispecific antibodies for GI cancers and solid tumors.